Lates News

According to the AI Express News, Huayuan Securities released a research report on August 25th, giving a buy rating to Jiudian Pharmaceutical (300705.SZ). The rating reasons mainly include: 1) the performance in the first half of 2025 meets expectations; 2) the pharmaceutical formulation continues to show stable growth, with a continuous enrichment of external patch product matrix; 3) the acquisition of the antibacterial peptide new drug JIJ02 gel, continuously strengthening the layout of the innovative drug pipeline. (Daily Economic News)